# Cannabidiol as an Adjunctive Treatment for Bipolar Depression

> **NCT03310593** · PHASE2,PHASE3 · TERMINATED · sponsor: **Hospital de Clinicas de Porto Alegre** · enrollment: 36 (actual)

## Conditions studied

- Bipolar Disorder
- Bipolar Depression
- Bipolar Affective Disorder

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03310593
- **Lead sponsor:** Hospital de Clinicas de Porto Alegre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-01
- **Primary completion:** 2020-02-24
- **Final completion:** 2020-03-24
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** It was interrupted due to the coronavirus pandemic outbreak.
- **Last updated:** 2021-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03310593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03310593, "Cannabidiol as an Adjunctive Treatment for Bipolar Depression". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03310593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*